8 results about "INSULIN USE" patented technology

The present disclosure relates to the use of a PFAS-free cannula in delivering a fluid medication, such as insulin, to a subcutaneous site. The cannula comprises polycarbonate polyurethane polysiloxane (PC-PU-PS), wherein the cannula is configured for subcutaneous insertion into the tissue of the individual in need thereof. The disclosure includes methods for administering insulin using the cannula and infusion devices comprising the cannula.

The present disclosure relates to a self-lubricating cannula for use in delivering a fluid medication to a subcutaneous site. The self-lubricating cannula comprises polyether block polyamide and an additive configured to facilitate the manufacture of a tipped self-lubricating cannula. The present disclosure also provides a method of making a self-lubricating cannula and a method of administering insulin using a self-lubricating cannula.

The present disclosure relates to a self-lubricating cannula for delivering a fluid drug to a subcutaneous site. The self-lubricating cannulas include a polyether block polyamide and an additive that are configured to facilitate the manufacture of tip self-lubricating cannulas. The present disclosure also provides a method of making the self-lubricating cannula and a method of administering insulin using the self-lubricating cannula.

The application discloses a kind of dabigatran bleeding risk prediction methods based on machine learning, it is related to computer-aided drug risk management technical field, the method is by obtaining patient baseline and follow-up data, multiple imputation method is handled missing value;With HAS-BLED score as the basis, candidate variables are screened from potential risk factors using LassoCV algorithm, and anemia, insulin use and antifungal agent use are determined as new prediction variables through clinical correlation analysis to construct a set of prediction variables;Finally, a random forest or gradient boosting algorithm is used to train the model to output the bleeding risk assessment results of the individual to be tested.The application combines machine learning algorithm, improves the prediction accuracy of dabigatran bleeding risk in Chinese non-valvular atrial fibrillation patients, solves the problem of insufficient prediction accuracy of traditional HAS-BLED score, and provides a more reliable basis for clinical individualized anticoagulant therapy decision.

The invention belongs to the field of biological agriculture, and discloses rumen bypass glucose based on a polymer gel technology and a preparation method and application thereof. The rumen bypass glucose is prepared from 15 to 30 parts of agar, 10 to 25 parts of zein, 5 to 15 parts of locust bean gum and 40 to 65 parts of anhydrous dextrose. The preparation method comprises the steps of raw material crushing, pre-melting, twin-screw melt extrusion, pelletizing, cooling, screening and the like. According to the invention, agar-locust bean gum is utilized to form a compact gel network to realize physical blocking and screening, and low release (in vitro 12-hour release rate lt, 5%) in rumen and rapid and complete release (in vitro 8-hour release rate gt, 90%) in small intestines are realized by relying on hydrophobicity and enzyme response characteristics of zein. The product is suitable for a feed for dairy cows in a perinatal period and an initial lactation period, can remarkably improve energy negative balance, shorten non-pregnant time by about 20 days and increase milk yield by about 3.0 kg / head per day, and is natural in raw materials, simple and convenient in process and suitable for industrial production.

The present disclosure relates to the use of a PFAS-free cannula in delivering a fluid drug, such as insulin, to a subcutaneous site. The cannula comprises a polycarbonate polyurethane polysiloxane (PC-PU-PS), wherein the cannula is configured for subcutaneous insertion into a tissue of an individual in need thereof. The present disclosure includes methods for administering insulin using the cannula and infusion devices including the cannula.

The invention relates to the field of medical instruments, in particular to an automatic insulin use assisting device and an application method thereof.The automatic insulin use assisting device comprises a control cylinder, an insulin pushing assembly is connected to the interior of the control cylinder, and an insulin pen fixing assembly is connected to the outer side of the lower end of the control cylinder and used for fixing an insulin pen; an exhaust monitoring assembly is connected to the outer sides of the control cylinder and the insulin pen fixing assembly. The insulin dosage can be automatically set, and the problem that patients with visual impairment and old people are difficult to accurately set the dosage is solved; due to the automatic exhaust function, the insulin injection accuracy is guaranteed, and injection errors caused by air residues are reduced; the voice broadcast function is convenient for old people and patients with visual impairment to use the insulin pen; the function associated with the mobile phone enables family members to know the insulin use condition of the patient in real time; through the detachable and recyclable design of the device arranged in the scheme, the economic burden of the patient is relieved.

The application discloses an automatic peritoneal dialysis method based on blood glucose dynamic monitoring, and comprises the following steps: acquiring blood glucose monitoring data of a user and diet time, carbohydrate intake, insulin use record, dialysate concentration and its ratio of the last peritoneal dialysis treatment of the user, extracting blood glucose key change points according to the same, and obtaining a blood glucose key structure sequence; constructing a blood glucose prediction model through a time series model, inputting the blood glucose key structure sequence into the pre-trained blood glucose prediction model to obtain a first blood glucose prediction sequence; taking blood glucose stability as a first layer optimization target based on the first blood glucose prediction sequence, calculating an optimal dialysate concentration and its ratio, updating the blood glucose key structure sequence according to the same, inputting the blood glucose prediction model, and obtaining a second blood glucose prediction sequence; calculating a blood glucose fluctuation risk index based on the second blood glucose prediction sequence, constructing a second layer stage control target according to the blood glucose fluctuation risk index of each peritoneal dialysis stage, and generating peritoneal dialysis control parameters.